human lung carcinoma epithelial cell line a549  (ATCC)

Journal: Biochemistry and Biophysics Reports

Article Title: Integrated transcriptomic and proteomic validation identifies SLC35D3 as a tumor-selective surface antigen for colorectal and neuroendocrine carcinomas

doi: 10.1016/j.bbrep.2026.102587

Figure Lengend Snippet: Immunohistochemical analysis of SLC35D3 expression in human tumors, normal tissues, and positive-control samples. (A) SLC35D3 staining in human tumors: (a) primary colon tumor; (b) corresponding lymph-node metastasis; (c) normal adjacent tissue (NAT) of a; (d) primary rectal tumor; (e) corresponding lymph-node metastasis; (f) NAT of d; (g–h) small-cell lung carcinoma (SCLC); (i) pancreatic neuroendocrine neoplasm; (j) pancreatic islet tumor. (B) SLC35D3 staining in human normal tissues: (a) cerebrum; (b) bone marrow; (c) lung; (d) heart; (e) liver; (f) kidney; (g) eye; (h) colon; (i) adrenal gland; (j) pancreas; (k) hypophysis; (l) stomach; (m) small intestine; (n) prostate. Arrowheads indicate SLC35D3-positive cells. (C) SLC35D3 staining of negative and positive control cell lines: (a) HCT 116-mock (negative control); (b) HCT 116-hSLC35D3 (engineered overexpression); (c) NCI–H1930 (endogenously SLC35D3-expressing).

Article Snippet: The human pancreatic islet cell carcinoma line QGP-1 (Japanese Collection of Research Bioresources Cell Bank, Osaka, Japan; Cat. No. JCRB0183), human small-cell lung carcinoma line NCI–H1930 (American Type Culture Collection (ATCC), Manassas, VA, USA; Cat. No. CRL-5906), human colorectal carcinoma line LoVo (ATCC; Cat. No. CCL-229), human gastric carcinoma line SNU-16 (ATCC; Cat. No. CRL-5974), and human colorectal carcinoma line HCT 116 (ATCC; Cat. No. CCL-247) were used.

Techniques: Immunohistochemical staining, Expressing, Positive Control, Staining, Negative Control, Over Expression

Journal: Biochemistry and Biophysics Reports

Article Title: Integrated transcriptomic and proteomic validation identifies SLC35D3 as a tumor-selective surface antigen for colorectal and neuroendocrine carcinomas

doi: 10.1016/j.bbrep.2026.102587

Figure Lengend Snippet: Validation of cell-surface SLC35D3 expression in cancer cell lines by flow cytometry and comparison with CCLE transcriptomic data. Flow cytometry histograms of cell-surface SLC35D3 staining in human cancer cell lines (HCT 116, LoVo, QGP-1, NCI–H1930, and SNU-16). For each cell line, the MFI ratio (anti-SLC35D3/isotype) and the corresponding mRNA expression level (log2[TPM+1]) from the CCLE are indicated below the histogram. HCT 116 served as a negative control and showed minimal surface staining, consistent with a CCLE value of log2[TPM+1] = 0.0.

Article Snippet: The human pancreatic islet cell carcinoma line QGP-1 (Japanese Collection of Research Bioresources Cell Bank, Osaka, Japan; Cat. No. JCRB0183), human small-cell lung carcinoma line NCI–H1930 (American Type Culture Collection (ATCC), Manassas, VA, USA; Cat. No. CRL-5906), human colorectal carcinoma line LoVo (ATCC; Cat. No. CCL-229), human gastric carcinoma line SNU-16 (ATCC; Cat. No. CRL-5974), and human colorectal carcinoma line HCT 116 (ATCC; Cat. No. CCL-247) were used.

Techniques: Biomarker Discovery, Expressing, Flow Cytometry, Comparison, Staining, Negative Control

Journal: bioRxiv

Article Title: Transgene Expression Kinetics and Replication Potential of Recombinant Adenovirus Serotype 4 in a Mouse Model and its Use as a Herpes Simplex Virus Vaccine

doi: 10.64898/2026.05.15.725395

Figure Lengend Snippet: Construction and characterization of Ad4 expressing luciferase or HSV-2 gD. (A) The E3 region of the adenovirus serotype 4 (Ad4) genome is replaced by left and right arms (LA, RA) to allow recombination with a cassette with LA, a CMV promoter, a luciferase or HSV-2 gD gene, a bovine growth hormone (BGH) poly A site, and an RA. The recombinant Ad4 genome is approximately 37 kb in length and retains genes in the E1 region responsible for viral replication. The genome map abbreviations are as follows; left inverted terminal repeat (LITR), E1-early transcriptional gene region 1 (consisting of E1A and E1B), E2-early transcriptional gene region 2 (consisting of E2A and E2B), E3-early transcriptional gene region 3, E4-early transcriptional gene region 4, and right inverted terminal repeat (RITR). (B) In vitro Ad4-Luc infection of A549 cells showing cytopathic effects (MOI 0.1, 3 days after infection, 5x magnification). (C) Uninfected A549 cells for comparison (5x magnification). (D) Relative luminescence of A549 cells infected with Ad4-Luc, Ad4-EGFP, or uninfected. Bars show median values with interquartile range (IQR), with individual data points. ## p=0.009 (Ad4-Luc versus Ad4-EGFP); ** p=0.002 (Ad4-Luc versus uninfected); ns: not significant. (E) Western blot of purified soluble HSV-2 gD protein (Sol gD2), cell lysates of A549 cells infected with Ad4-gD2 (Ad4-gD2), a replicate lysate (Ad4-gD2 rep), and uninfected A549 cells after staining with anti-HSV-2 gD antibody.

Article Snippet: The previously described SpeI site was utilized to linearize pRAd4-EGFP or pRAd4-Luc and this was transfected using PEIpro® (Polyplus Cat# 101000033) into the A549 human carcinoma lung cell line (ATCC cat. CCL-185).

Techniques: Expressing, Luciferase, Recombinant, In Vitro, Infection, Comparison, Western Blot, Purification, Staining

Journal: iScience

Article Title: Drug screening to identify compounds to eliminate Burkholderia pseudomallei through Hcp protein

doi: 10.1016/j.isci.2026.115367

Figure Lengend Snippet: Netilmicin sulfate alone and in combination exerted protective effects on an infected A549 cell model (A) Cytotoxic effects of the drugs on A549 cells. (B) Protective effects of different concentrations of NETS on A549 cells. The early interventions on the abscissa reflect the incubation of A549 cells with the drug for 2 h before B. pseudomallei HNBP001 infection. Late intervention was defined as the introduction of the drug to A549 cells 2 h after infection with B. pseudomallei HNBP001 . The ordinate is the survival rate of the infected A549 cells. NC: the blank negative control group of fresh 10% DMEM. Bp: infected A549 cell group. Bp+30 μM NETS: The infected A549 cells were treated with 30 μM NETS; the other conditions were the same, but different concentrations of NETS were used. (C) Protective effects of several drugs on infected A549 cells; the ordinate is the survival rate of infected A549 cells. NC, blank negative control group of fresh 10% DMEM. Bp: infected A549 cell group. Other: The infected A549 cells were treated with drugs (including SXT, GM, NETS, CAZ, and NETS+CAZ). (D) Number of intracellular bacteria in infected A549 cells after drug treatment; the ordinate represents the number of bacteria in infected A549 cells. NC is the blank negative control group of fresh 10% DMEM. Bp: infected A549 cell group. Drug group: 2 × MIC drug was used to treat infected A549 cells. All drugs, including SXT, GM, NETS, CAZ, and NETS+CAZ. (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001; ns, no significant difference. Data are represented as mean ± SEM.).

Article Snippet: The A549 human lung carcinoma epithelial cell line was purchased from Procell (Wuhan, China; Cat# CL-0016).

Techniques: Infection, Incubation, Negative Control, Bacteria

Journal: iScience

Article Title: Drug screening to identify compounds to eliminate Burkholderia pseudomallei through Hcp protein

doi: 10.1016/j.isci.2026.115367

Figure Lengend Snippet: Netilmicin sulfate alone and in combination exerted protective effects on an infected A549 cell model (A) Cytotoxic effects of the drugs on A549 cells. (B) Protective effects of different concentrations of NETS on A549 cells. The early interventions on the abscissa reflect the incubation of A549 cells with the drug for 2 h before B. pseudomallei HNBP001 infection. Late intervention was defined as the introduction of the drug to A549 cells 2 h after infection with B. pseudomallei HNBP001 . The ordinate is the survival rate of the infected A549 cells. NC: the blank negative control group of fresh 10% DMEM. Bp: infected A549 cell group. Bp+30 μM NETS: The infected A549 cells were treated with 30 μM NETS; the other conditions were the same, but different concentrations of NETS were used. (C) Protective effects of several drugs on infected A549 cells; the ordinate is the survival rate of infected A549 cells. NC, blank negative control group of fresh 10% DMEM. Bp: infected A549 cell group. Other: The infected A549 cells were treated with drugs (including SXT, GM, NETS, CAZ, and NETS+CAZ). (D) Number of intracellular bacteria in infected A549 cells after drug treatment; the ordinate represents the number of bacteria in infected A549 cells. NC is the blank negative control group of fresh 10% DMEM. Bp: infected A549 cell group. Drug group: 2 × MIC drug was used to treat infected A549 cells. All drugs, including SXT, GM, NETS, CAZ, and NETS+CAZ. (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001; ns, no significant difference. Data are represented as mean ± SEM.).

Article Snippet: A549 human lung carcinoma cell line , Procell , Cat#CL-0016.

Techniques: Infection, Incubation, Negative Control, Bacteria